Recently, former Congressman Patrick Kennedy visited Moberg Research’s (Moberg) medical device manufacturing facility. Rep. Kennedy and Dick Moberg discussed how Moberg’s advanced neurological monitors facilitate cutting-edge research in neurological disease and treatment.
In 2011, Rep. Kennedy and mental health advocate, Garen Staglin, created One Mind, a 501(c)(3) non-profit organization dedicated to fostering fundamental changes that will radically accelerate the development and implementation of improved diagnostics, treatments and cures for diseases and injuries of the brain, while eliminating the stigma and discrimination that persists. During 16 years in the U.S. House of Representatives, Rep. Kennedy authored and co-sponsored dozens of bills to increase understanding and treatment of neurological and psychiatric disorders. Now, One Mind, which unites governmental, corporate, scientific, and philanthropic communities, is poised to lead research, funding, and public awareness of mental illness and brain injury.
For 30 years, Dick Moberg has led companies that create medical devices and technologies for care of brain injured patients. Currently, Moberg offers a commercial patient monitor that provides comprehensive neurological data integration to support caregivers’ abilities to provide timely, effective treatment. Moberg’s products will be used in international brain injury research studies supported by One Mind.
Moberg and One Mind share the goal of giving scientists and physicians access to integrated data to enhance brain injury care and research. Data integration is a tenet of One Mind’s Open Science Principles, which assert that open-source big data and research will decrease time from initial research to cure.
Moberg will provide brain monitors for data integration in One Mind’s inaugural projects, Track-TBI and Center-TBI. These clinical studies will investigate traumatic brain injury (TBI) and post-traumatic stress (PTS) with support from National Institutes of Health (NIH), U.S. Department of Defense (DOD), and European Commission. The studies will result in databases available to all researchers, which will be particularly valuable for those studying diseases with similar biological characteristics.
